A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
AbstractTumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by the complicated and coordinated actions of pro-angiogenic factors and their receptors that become upregulated during tumorigenesis. Over the past several decades, vascular endothelial growth factor (VEGF) signaling has been identified as a central axis in tumor angiogenesis. The remarkable advent of recombinant antibody technology has led to the development of bevacizumab, a humanized antibody that targets VEGF and is a leading clinical therapy to suppress tumor angiogenesis. However, despite the clinical efficacy of bevacizumab, its significant side effects and drug resistance have raised concerns necessitating the identification of novel drug targets and development of novel therapeutics to combat tumor angiogenesis. This review will highlight the role and relevance of VEGF and other potential therapeutic targets and their receptors in angiogenesis. Simultaneously, we will also cover the current status of monoclonal antibodies being developed to target these candidates for cancer therapy. View Full-Text
Share & Cite This Article
Kong, D.-H.; Kim, M.R.; Jang, J.H.; Na, H.-J.; Lee, S. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. Int. J. Mol. Sci. 2017, 18, 1786.
Kong D-H, Kim MR, Jang JH, Na H-J, Lee S. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. International Journal of Molecular Sciences. 2017; 18(8):1786.Chicago/Turabian Style
Kong, Deok-Hoon; Kim, Mi R.; Jang, Ji H.; Na, Hee-Jun; Lee, Sukmook. 2017. "A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy." Int. J. Mol. Sci. 18, no. 8: 1786.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.